Press release
HIV-Associated Lipodystrophy Treatment Market Outlook Across Hospitals Retail and Online Pharmacies
HIV-Associated Lipodystrophy Treatment Market
According to the latest research by InsightAce Analytic, the Global HIV-Associated Lipodystrophy Treatment Market is valued at USD 176.82 Mn in 2023, and it is expected to reach USD 239.62 Mn by the year 2031, with a CAGR of 4.05% during the forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2250
HIV-associated lipodystrophy is a clinical condition commonly observed in individuals living with HIV, characterized by abnormal alterations in body fat distribution. These changes often manifest as a reduction of subcutaneous fat in regions such as the face, buttocks, arms, and legs. While the precise etiology is not fully understood, evidence indicates a potential link between antiretroviral therapy and the onset of this condition. Clinically, lipodystrophy typically presents in two forms, which may coexist: lipoatrophy, involving the loss of subcutaneous fat, and central adiposity, characterized by increased fat accumulation in the abdominal area.
These physical manifestations can have a substantial impact on patients' psychological well-being, including self-esteem and body image. A variety of therapeutic interventions are available to address the associated morbidity. Effective management of HIV-associated lipodystrophy requires a multidisciplinary approach, encompassing accurate diagnosis and personalized treatment planning. Notably, newer-generation antiretroviral therapies have been associated with a reduced risk of inducing lipodystrophy, reflecting significant advancements in drug safety and tolerability.
List of Prominent Players in the HIV-associated lipodystrophy treatment market:
• Theratechnologies Inc.
• GlaxoSmithKline plc
• Novelion Therapeutics Inc.
• AstraZeneca plc
• AbbVie Inc.
• Bristol-Myers Squibb
• Amryt Pharmaceuticals, Inc.,
• Fawn Incorporation,
• Abbott Healthcare Solutions,
• Lupin Pharmaceuticals, Inc.,
• Pfizer Inc.,
• Bayer Inc.,
• Novartis Pharmaceuticals Corporation,
• Galderma Laboratories, L.P.
• Others
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04
Market Dynamics
Drivers:
The growth of the HIV-associated lipodystrophy treatment market is largely driven by the potential metabolic benefits associated with managing the condition, including a reduced risk of atherosclerosis and type 2 diabetes in certain patient populations. The widespread adoption of antiretroviral therapy (ART) has markedly improved the overall health outcomes of individuals living with HIV by effectively suppressing viral replication. These therapeutic advancements not only enhance patient quality of life but also play a critical role in reducing HIV transmission rates, further supporting market expansion.
Challenges:
Despite favorable growth prospects, the market faces several challenges. Limited awareness of HIV-associated lipodystrophy, a shortage of specialized healthcare professionals, and the absence of standardized diagnostic and treatment protocols-particularly in developing regions-remain key barriers to market development. Additional obstacles include restricted drug availability, suboptimal patient adherence, co-morbidities and opportunistic infections, and insufficient disease management frameworks.
The psychological impact of the condition, including depression, low self-esteem, and social isolation, further exacerbates patient distress. Metabolic complications, such as insulin resistance, hyperlipidemia, and hyperglycemia, increase cardiovascular risk within this population. Importantly, COVID-19 vaccines are considered safe for individuals with HIV and are compatible with existing prevention and treatment regimens.
Regional Trends:
North America is expected to maintain a dominant share of the global market, supported by favorable healthcare policies and initiatives. For example, certain regions, such as Massachusetts, have extended insurance coverage to include side effects of HIV medications, including lipodystrophy, a measure that could further stimulate regional market growth if widely implemented. In Europe, rising HIV prevalence and growing demand for targeted therapies have strengthened market presence. Globally, the HIV-associated lipodystrophy treatment market is projected to experience steady growth, underpinned by increasing awareness, ongoing advancements in therapeutic technologies, and a continued focus on improving patient outcomes.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2250
Segmentation of HIV-Associated Lipodystrophy Treatment Market-
By lipodystrophy type,
• Lipoatrophy
• Lipoaccumulation
By therapeutic class,
• Anabolism modulators
• Growth hormones
• Anabolic steroids
• Insulin resistance modulators
• Metformins
• Thiazolidinediones
• Mitochondrial antioxidants (l-carnitine)
• Other miscellaneous metabolic agents
By distribution channel,
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/hiv-associated-lipodystrophy-treatment-market/2250
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HIV-Associated Lipodystrophy Treatment Market Outlook Across Hospitals Retail and Online Pharmacies here
News-ID: 4320092 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
KRAS Inhibitors Market Driven by Precision Medicine and Targeted Oncology Therap …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global KRAS Inhibitors Market - (By Cancer Type (Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Others), By End-Use (Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global KRAS Inhibitors Market is valued at USD 476.0…
Stem Cell Therapy for Respiratory Disorders Market Analysis on Opportunities for …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Stem Cell Therapy for Respiratory Disorders Market Size, Share & Trends Analysis Report (By Indications (Acute Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension), Cell Type (Mesenchymal Stem Cells, EV/Exosomes, iPSC Lung cells, Endothelial Progenitor Cells)),-Market Outlook And Industry Analysis 2034"
Global Stem Cell Therapy for Respiratory Disorders Market…
Self-urinary Infection Testing Market Research on Rising Demand for At-home UTI …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Self-urinary Infection Testing Market Size, Share & Trends Analysis Report By Product (Urine Assay Kit, Dipsticks, Home Protein Urine Test Strips, and Creatinine Urine Diagnostic Test Kit), By Application (Diabetes, Kidney Diseases, Urinary Tract Infections, and Others), By End-use (Hospitals Clinics, Diagnostic Laboratories, Home Care Settings, Research Laboratories Institutes, and Assisted Living Healthcare Facilities),-Market Outlook…
Erectile Dysfunction Devices Market Growth and Restrain Factors Analysis Report
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Erectile Dysfunction Devices Market Size, Share & Trends Analysis Report By Product (Implants, Shockwave Therapy Devices, Vacuum Therapy Devices, Others), By Approach (Invasive and Non-Invasive), By End-User (Hospitals, Ambulatory Surgical Centers (ASCs)), Region, Market Outlook And Industry Analysis 2031"
The Global Erectile Dysfunction Devices Market is estimated to reach over USD 3.62 billion by 2031, exhibiting…
More Releases for HIV
HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792
This latest report researches the industry structure, sales, revenue,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
